Cargando…
The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
BACKGROUND: Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). No reports are known of treatment after sunitinib failure. As irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy has been reported to influence MCRC after progression on cytokine therap...
Autores principales: | Powles, Thomas, McFaul, Siobhan, Stebbing, Justin, Wilson, Peter, Oliver, Tim, Tranter, Naomi, Shamash, Jonathan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994212/ https://www.ncbi.nlm.nih.gov/pubmed/21127750 |
Ejemplares similares
-
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers – a new active regimen
por: Slater, S, et al.
Publicado: (2002) -
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011) -
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
por: Powles, T, et al.
Publicado: (2003) -
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
por: Shamash, J, et al.
Publicado: (2011) -
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)